Previous 10 | Next 10 |
2024-04-12 10:00:50 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Drug...
2024-04-12 08:00:07 ET Julian Harrison from BTIG issued a price target of $21.00 for TBPH on 2024-04-12 06:36:00. The adjusted price target was set to $21.00. At the time of the announcement, TBPH was trading at $8.93. The overall price target consensus is at $14.00 with...
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 PR Newswire DUBLIN , ...
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire Q4 2023 YUPELRI ® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million ...
SUIC Worldwide Holdings Ltd (SUIC) is expected to report for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 uniQure N.V. (QURE) is expected to report $-1.54 for Q4 2023 Albany International Corporation (AIN) is expected to report $0.84 for Q4 2023 I...
2024-02-25 17:35:04 ET Major earnings expected after the bell on Monday include: Zoom Video Communications ( ZM ) Unity Software ( U ) ONEOK ( OKE ) Innovative Industrial Properties ( IIPR ) Workday ( WDAY ) Read the full article on Seeking ...
2024-02-23 20:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 PR Newswire DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2023 financial result...
2024-02-13 20:45:43 ET Summary Baupost Group's 13F portfolio value decreased from $5.21B to $4.59B this quarter. The portfolio is heavily concentrated with Liberty Global, Liberty SiriusXM, Viasat, Alphabet, and Fidelity National Information Services accounting for ~62% of the hol...
2024-01-16 08:19:18 ET Orbicular Pharmaceutical Technologies has agreed to resolve its patent fight with Theravance Biopharma ( NASDAQ: TBPH ) and Viatris ( NASDAQ: VTRS ) unit, Mylan, over the respiratory disorder therapy Yupelri. Per the terms of the agreement, Orbicul...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...